Evidence map›Paper›PMID 41118107›Full record

ArticleInternal and emergency medicine2026

Bridging innovation and clinical impact: advances and challenges in beta cell replacement therapies.

Muhammad Naveed, Uzair Ahmad Mahar, Muhammad Mustafa, Wajiha Asim

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Muhammad NaveedFederal Medical and Dental College, Shaheed Zulfiqar Ali Bhutto Medical University, Opp. NORI Hospital, Islamabad, G8/4, Pakistan. mnaveed2022@fmdc.edu.pk.ORCID 0009-0001-9071-1505
Uzair Ahmad MaharDow Medical College, Dow University of Health Sciences, Karachi, 74600, Sindh, Pakistan.ORCID 0009-0006-3734-5709
Muhammad MustafaDow International Medical College, Dow University of Health Sciences, Karachi, 74600, Sindh, Pakistan.ORCID 0009-0008-3534-4141
Wajiha AsimDow International Medical College, Dow University of Health Sciences, Karachi, 74600, Sindh, Pakistan.ORCID 0009-0005-6715-6805

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This letter explores recent innovations and challenges in beta cell replacement therapies for diabetes, emphasizing the gap between promising bioengineering techniques and clinical applicability. While advancements like stem cell-derived beta cells and bioartificial pancreas models show potential, concerns remain regarding immune rejection, maturation of beta cells, and long-term safety. Current strategies lack focus on type 2 diabetes, which constitutes the majority of cases. Moreover, issues such as vascularization, fibrosis, and ethical implications require further exploration. Bridging scientific breakthroughs with real-world application necessitates rigorous preclinical validation and scalability strategies to ensure safe, effective, and inclusive treatment for the global diabetic population.

Indexed as

Diabetes Mellitus, Type 2Insulin-Secreting CellsInventionsHumansBioengineeringDiabetes mellitusGenetic therapyImmune systemInsulin resistanceTechnologyType 1

Identifiers

PMID41118107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.